Prime Medicine, Inc. (CIK: 0001894562) EDGAR, Information, Filings... CompaniesBIO.Com

Prime Medicine, Inc.

Mailing address
21 ERIE ST., CAMBRIDGE, Delaware, 02139
Phone
617-465-0013
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Prime Medicine, Inc. (CIK: 0001894562) is an American company incorporated in the state of Massachusetts. Head office is located at 21 ERIE ST., CAMBRIDGE, Massachusetts, 02139. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Prime Medicine, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Marrazzo Jeffrey D	0001631262	May-10-2023	director
Alphabet Inc.	0001652044	May-08-2023	10 percent owner
GV 2019 GP, L.L.C.	0001845038	May-08-2023	10 percent owner
GV 2019 GP, L.P.	0001845039	May-08-2023	10 percent owner
GV 2019, L.P.	0001845041	May-08-2023	10 percent owner
GV 2021, L.P.	0001861202	May-08-2023	10 percent owner
GV 2021 GP, L.L.C.	0001861206	May-08-2023	10 percent owner
GV 2021 GP, L.P.	0001861216	May-08-2023	10 percent owner
FMR LLC	0000315066	Oct-19-2022	10 percent owner, other: See Remark 1
CRANDELL KEITH	0001219039	Oct-19-2022	10 percent owner
NELSEN ROBERT	0001219042	Oct-19-2022	director, 10 percent owner
GILLIS STEVEN	0001229592	Oct-19-2022	10 percent owner
Foster-Cheek Kaye I	0001312622	Oct-19-2022	director
Burow Kristina	0001569248	Oct-19-2022	10 percent owner
Schenkein David P	0001578200	Oct-19-2022	director
Gottesdiener Keith Michael	0001615856	Oct-19-2022	director, officer: See Remarks
Liu David R.	0001664439	Oct-19-2022	10 percent owner
Alenson Carman	0001688865	Oct-19-2022	officer: See Remarks
Brudnick Richard	0001692359	Oct-19-2022	officer: Chief Business Officer
LEE ANN L.	0001723629	Oct-19-2022	officer: Chief Technical Officer
ARCH Venture Fund X, L.P.	0001757011	Oct-19-2022	10 percent owner
ARCH Venture Fund X Overage, L.P.	0001757017	Oct-19-2022	10 percent owner
ARCH Venture Partners X Overage, L.P.	0001768905	Oct-19-2022	10 percent owner
ARCH Venture Partners X, LLC	0001769012	Oct-19-2022	10 percent owner
Kelly Michael Aaron	0001769668	Oct-19-2022	director
ARCH Venture Partners X, L.P.	0001782583	Oct-19-2022	10 percent owner
Duffield Jeremy	0001922590	Oct-19-2022	officer: Chief Scientific Officer
Chung Wendy	0001922605	Oct-19-2022	director
Goldwasser Meredith	0001922606	Oct-19-2022	officer: SVP, Strategy & Corporate Ops.
Cahill Thomas	0001922939	Oct-19-2022	director

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Prime Medicine, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001628280-26-053883 (34 Act) Size: KB	Aug-06-2026	001-41536 261246127
8-K	Document	Current report filing Acc-no: 0001628280-26-053878 (34 Act) Size: KB	Aug-06-2026	001-41536 261246116
8-K	Document	Current report filing Acc-no: 0001628280-26-047590 (34 Act) Size: KB	Jul-08-2026	001-41536 261160797
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041579 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041575 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041572 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041569 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041566 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041560 ( Act) Size: 0 KB	Jun-08-2026
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001628280-26-041553 ( Act) Size: 0 KB	Jun-08-2026
8-K	Document	Current report filing Acc-no: 0001628280-26-041543 (34 Act) Size: KB	Jun-08-2026	001-41536 261072719
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001628280-26-031726 (34 Act) Size: KB	May-07-2026	001-41536 26950997
8-K	Document	Current report filing Acc-no: 0001628280-26-031719 (34 Act) Size: KB	May-07-2026	001-41536 26950980
ARS	Document	Annual report to security holders Acc-no: 0001628280-26-026704 (34 Act) Size: KB	Apr-23-2026	001-41536 26885792
DEFA14A	Document	Additional definitive proxy solicitation materials Acc-no: 0001628280-26-026701 (34 Act) Size: KB	Apr-23-2026	001-41536 26885745
DEF 14A	Document	Definitive proxy statements Acc-no: 0001628280-26-026697 (34 Act) Size: KB	Apr-23-2026	001-41536 26885734
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001470831-26-000388 ( Act) Size: 0 KB	Apr-17-2026
3	Document	Initial statement of beneficial ownership of securities Acc-no: 0001470831-26-000386 ( Act) Size: 0 KB	Apr-17-2026
8-K	Document	Current report filing Acc-no: 0001628280-26-025372 (34 Act) Size: KB	Apr-16-2026	001-41536 26865756
EFFECT	Document	Acc-no: 9999999995-26-000723 (33 Act) Size: KB	Mar-04-2026	333-291348 26724020

Recent 20 filings. View all Prime Medicine, Inc. filings

Overall rating 5.0

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Prime Medicine, Inc. overview
Prime Medicine, Inc. job
Prime Medicine, Inc. stock
Prime Medicine, Inc. ownership
Prime Medicine, Inc. CEO
Prime Medicine, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.